港股異動 | 海吉亞醫療(6078.HK)股價續創歷史新高 市值逼近500億港元
格隆匯5月24日丨海吉亞醫療(6078.HK)今日盤中一度漲近5%至80.75港元續創歷史新高,市值逼近500億港元;現報78.8港元,漲幅收窄至2.2%,暫成交3億港元,最新市值486.98億港元,該股暫七日連升累漲超30%,年內已累漲超60%。中信證券最新發研報指,海吉亞醫療為中國最大腫瘤醫療集團,管理團隊醫療及管理經驗深厚;公司核心醫院精益運營,立體化醫療網絡全面推進。首予其“買入”評級,目標價83.5港元,預計2021-23年攤薄後EPS為0.66/0.92/1.25元(對應0.79/1.11/1.51港元)。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.